Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|June 3, 2022
Cambrex Acquires Irish Storage Company Q1 Scientific
Author(s)BioPharm International Editors
Cambrex’s acquisition of Q1 Scientific expands the company’s storage services in the European market.
Advertisement
Cambrex announced on June 1, 2022 that it had acquired Q1 Scientific, an Irish provider of environmentally-controlled current good manufacturing practices (cGMP) stability storage services for the pharmaceutical, medical device, and life science industries.
According to a company press release, Q1’s Scientific's cGMP facility is validated to meet specific storage requirements for the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human (ICH). The 20,000 ft² facility has approximately 40 walk-in stability storage chambers, reach-in freezers, and stability units, as well as ultra-low temperature freezers for biologic therapies. In addition to these storage capabilities, the company also provides sample management and transport services.
“Stability storage and testing is a critical component of drug development and commercialization of new therapies.,” said Tom Loewald, CEO, Cambrex, in the press release. “This acquisition is a natural extension of our current offerings that will broaden and increase our expertise in this critical area, as well as our footprint in the European market.”
“We’re pleased to join Cambrex as we continue to provide leading stability storage services to our current customers,” said Stephen Delaney, CEO, Q1 Scientific, in the press release. “With Cambrex’s scientific expertise and scale, we’ll be able to accelerate our growth and offer an integrated suite of analytical services, providing a full range of market-leading solutions for our customers.”
Source:
Advertisement
Related to this article
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
CordenPharma is expanding its Caponago, Italy site with a €80 million multi-year investment and new aseptic fill-finish lines, aiming to reach 500 million sterile injectable units of annual capacity to meet rising demand across peptide, biologic, LNP, and oligonucleotide-based drug products.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Encoded Therapeutics closed a $275 million Series F financing to fund pivotal and expansion studies of ETX101, an AAV9-mediated gene regulation therapy for SCN1A-positive Dravet syndrome, alongside commercial-scale buildout of the company's in-house GMP manufacturing.
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.
Advertisement
Advertisement